A molecular gum degrader targeting phosphorylated Tau, its preparation method and application

By designing a small molecule gel degrader with a Tau binding module and a 4-trifluoromethylcinnamoyl structure, the limitations of traditional PROTAC in the central nervous system have been overcome. This approach achieves selective clearance of multiple phosphorylated Tau epitopes, reduces the neurotoxicity of Tau protein, and provides a new therapeutic strategy.

CN123106664APending Publication Date: 2026-11-17CHINA PHARM UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611193007.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-07
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies are unable to effectively degrade abnormal phosphorylation of Tau protein, and traditional PROTACs have large molecular weights, complex structures, and are not suitable for applications in the central nervous system.

Method used

A class of compact small molecule gel degraders was designed, utilizing a Tau binding module and a 4-trifluoromethylcinnamoyl structure to remove pathologically phosphorylated Tau protein through the intracellular ubiquitin-proteasome system.

Benefits of technology

This study achieved selective clearance of multiple phosphorylated Tau epitopes, reducing the neurotoxic effects of Tau protein and providing a new strategy for treating Tau-related neurodegenerative diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106664A_ABST
    Figure CN123106664A_ABST
Patent Text Reader

Abstract

This invention discloses a molecular glue degrader targeting phosphorylated Tau, its preparation method, and its applications. The general structural formula of this molecular glue degrader is shown in Formula I. This invention uses a Tau-binding module as the recognition unit and introduces a 4-trifluoromethylcinnamoyl chemical handle, with representative compounds including DT1, DT2, DT3, and DT4. Experimental results show that these compounds can reduce the level of disease-related phosphorylated Tau protein in cells. The molecular glue degrader of this invention can be used to prepare drugs for the prevention, alleviation, and / or treatment of neurodegenerative diseases characterized by abnormal phosphorylation of Tau protein.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a molecular glue degrader that targets phosphorylated Tau and its preparation method, as well as its application in the preparation of drugs for the prevention, relief and / or treatment of neurodegenerative diseases characterized by abnormal phosphorylation of Tau protein. Background Technology

[0002] Alzheimer's disease is a common neurodegenerative disease, primarily characterized by cognitive and memory decline. Abnormal phosphorylation, misfolding, aggregation, and neurofibrillary tangles of Tau protein are important pathological features of Alzheimer's disease and various Tau protein disorders. Pathological phosphorylated Tau protein is closely related to neuronal dysfunction, disease progression, and cognitive decline; therefore, reducing the level of pathologically phosphorylated Tau protein is an important strategy for intervening in Tau-related neurodegenerative diseases.

[0003] Targeted protein degradation technology can clear disease-related proteins by leveraging the intracellular ubiquitin-proteasome system. Traditional PROTACs typically consist of a target protein ligand, a linker chain, and an E3 ligase ligand. While they have the ability to induce protein degradation, they are characterized by large molecular weight, complex structural optimization, strong linker chain dependence, and potential limitations in brain tissue distribution and pharmacokinetic properties when used for central nervous system diseases.

[0004] Molecular glue degraders are a class of small molecule compounds that can induce or enhance the interaction between target proteins and E3 ligases or related protein quality control systems. Compared with heterobifunctional PROTACs, molecular glue degraders have a more compact structure and do not necessarily require long linker chains and independent E3 ligase ligands, thus holding promise for the development of small molecule degraders more suitable for central nervous system diseases.

[0005] Currently, compact small-molecule gel degraders targeting phosphorylated Tau protein are still under development. Therefore, constructing gel degraders capable of reducing phosphorylated Tau epitopes associated with multiple diseases has significant research value and application prospects. Summary of the Invention

[0006] Objectives of the Invention: One objective of this invention is to provide a molecular gel degrader that targets phosphorylated Tau. Another objective of this invention is to provide a method for preparing the molecular gel degrader. A final objective of this invention is to provide the use of the molecular gel degrader in the preparation of drugs for the prevention, relief, and / or treatment of neurodegenerative diseases characterized by abnormal phosphorylation of Tau protein.

[0007] Technical solution: The present invention provides a molecular gel degrader targeting phosphorylated Tau, or a pharmaceutically acceptable salt, solvate, crystal form, isotope label, or prodrug thereof, wherein the molecular gel degrader has the general structural formula shown in Formula I:

[0008]

[0009] Where R is or n is an integer between 0 and 6.

[0010] The molecular adhesive degrader is selected from any of the following structures:

[0011] , , , .

[0012] A method for preparing a molecular gel degrader targeting phosphorylated Tau as described in this invention, or its pharmaceutically acceptable salt, solvate, crystal form, isotope label, or prodrug, synthesized according to the following route:

[0013] .

[0014] Specifically, it includes the following steps:

[0015] 4-Trifluoromethylcinnamic acid and a condensing agent were added to an organic solvent, followed by the addition of an organic base. The mixture was stirred and activated under a protective gas atmosphere. Compound II (a piperazine-containing Tau-binding module) was then added to continue the reaction. The mixture was then extracted, dried, concentrated, and purified by column chromatography.

[0016] The condensing agent is one or more of HATU (2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate), HBTU (O-benzotriazole-tetramethylurea hexafluorophosphate), EDCI (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide), DCC (N,N'-dicyclohexylcarbodiimide), or T3P (propyl phosphoric anhydride), preferably HATU; the organic solvent is one or more of N,N-dimethylformamide, dichloromethane, dimethyl sulfoxide, acetonitrile, and tetrahydrofuran, preferably N,N-dimethylformamide; and the organic base is one or more of N,N-diisopropylethylamine, triethylamine, pyridine, or N-methylmorpholine, preferably N,N-diisopropylethylamine. The molar ratio of compound II, 4-trifluoromethylcinnamic acid, condensing agent, and organic base is 1:(1.0-1.5):(1.2-3.0):(2.0-6.0), preferably 1:1.1:2:4. Nitrogen is used as the protective gas; the stirring activation time is 20-60 min, preferably 30 min; the reaction temperature is 15-35℃, preferably room temperature, and the reaction time is at least 12 h. After the reaction, the target compound is obtained by extraction with ethyl acetate, drying with anhydrous sodium sulfate, concentration under reduced pressure, and purification by silica gel column chromatography.

[0017] The present invention also includes a pharmaceutical composition comprising the molecular gel degrader described herein or a pharmaceutically acceptable salt, solvate, crystal form, isotope label, or prodrug thereof.

[0018] The drug also includes pharmaceutically acceptable carriers, excipients, diluents, stabilizers, buffers, solubilizers, emulsifiers, and / or isotonic agents. The dosage form of the pharmaceutical composition is one of the following: pills, tablets, capsules, granules, oral liquids, injections, lyophilized powder for injection, liposome formulations, nanoparticle formulations, nasal administration formulations, or intravenous injections.

[0019] The use of the molecular gel degrader of the present invention or its pharmaceutically acceptable salt, solvate, crystal form, isotope label or prodrug, or the pharmaceutical composition of the present invention, in the preparation of a medicament for the prevention, relief and / or treatment of neurodegenerative diseases characterized by abnormal phosphorylation of Tau protein.

[0020] Among them, neurodegenerative diseases include Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, Pick's disease, corticobasal degeneration and / or argyrophilic granuloma.

[0021] This invention targets pathologically phosphorylated Tau protein, investigating novel and highly efficient Tau molecular glue degraders. Furthermore, it explores the therapeutic effects of these degraders, specifically promoting the clearance of pathological Tau protein and reducing its neurotoxicity. Specifically, a Tau-binding module is used as a targeting group to enhance the compound's recognition of Tau protein and its aberrant phosphorylated forms. A series of small-molecule degraders specifically targeting phosphorylated Tau protein are constructed using a 4-trifluoromethylcinnamoyl structure as a molecular glue functional handle. Cellular experiments verify that these degraders can reduce the level of multi-site phosphorylated Tau protein. The Tau molecular glue degraders of this invention are characterized by their compact structure and lack of the need for traditional long PROTAC linkers, making them a promising approach for treating neurodegenerative diseases characterized by abnormal Tau protein aggregation, thus providing new possibilities for the treatment of Tau-related neurodegenerative diseases.

[0022] Beneficial Effects: Compared with the prior art, the present invention has the following significant advantages: (1) The present invention is the first to construct a class of small molecule molecular glue degraders targeting pathological phosphorylated Tau protein, which can be used to promote the selective clearance of disease-related Tau protein, providing a new intervention strategy for neurodegenerative diseases characterized by abnormal Tau protein aggregation. (2) The molecular glue degraders of the present invention have a core structure of Tau binding module and 4-trifluoromethylcinnamoyl functional handle, with a compact overall structure that does not rely on the long linker chain and independent E3 ligase ligand commonly used in traditional PROTAC, which is conducive to subsequent optimization of drug-like properties of the central nervous system. (3) The representative compounds of the present invention can reduce the level of multiple disease-related phosphorylated Tau epitopes, indicating that these compounds do not only act on a single phosphorylation site, but have a broad potential for clearing pathological Tau protein. (4) The molecular glue degraders of the present invention can be used as candidate active ingredients for the preparation of drugs for the prevention, relief or treatment of Tau protein diseases, and can also be used as experimental reagents for studying the pathological mechanism of phosphorylated Tau, with good scientific research and drug development application value. Attached Figure Description

[0023] Figure 1 The NMR fluorine spectrum of DT1, a molecular adhesive degrader;

[0024] Figure 2 The 1H NMR spectrum of DT1, a molecular adhesive degrader;

[0025] Figure 3 The carbon NMR spectrum of DT1, a molecular adhesive degrader;

[0026] Figure 4 High-resolution mass spectrum of DT1, a molecular adhesive degrader;

[0027] Figure 5 The NMR fluorine spectrum of DT2, a molecular adhesive degrader;

[0028] Figure 6 The 1H NMR spectrum of DT2, a molecular adhesive degrader;

[0029] Figure 7 The carbon NMR spectrum of DT2, a molecular adhesive degrader;

[0030] Figure 8 High-resolution mass spectrum of DT2, a molecular adhesive degrader;

[0031] Figure 9 The NMR fluorine spectrum of DT3, a molecular adhesive degrader;

[0032] Figure 10 The 1H NMR spectrum of DT3, a molecular adhesive degrader;

[0033] Figure 11The carbon NMR spectrum of DT3, a molecular adhesive degrader;

[0034] Figure 12 High-resolution mass spectrum of DT3, a molecular adhesive degrader;

[0035] Figure 13 The NMR fluorine spectrum of DT4, a molecular adhesive degrader;

[0036] Figure 14 The 1H NMR spectrum of DT4, a molecular adhesive degrader;

[0037] Figure 15 The carbon NMR spectrum of DT4, a molecular adhesive degrader;

[0038] Figure 16 High-resolution mass spectrum of DT4, a molecular adhesive degrader;

[0039] Figure 17 This is a diagram showing the dose-dependent experimental results of DT1, DT2, and DT4 reducing p-Tau levels at multiple sites in Example 5. Detailed Implementation

[0040] The technical solution of the present invention will be further described below with reference to the accompanying drawings and embodiments.

[0041] Example 1: Preparation of DT1, a molecular adhesive degrader

[0042] Synthesize according to the following route:

[0043] 24 mg of 4-trifluoromethylcinnamic acid and 64 mg of HATU were added to a reaction flask, along with 2.00 mL of N,N-dimethylformamide as a solvent. After stirring, 86 mg of N,N-diisopropylethylamine was added, and the mixture was evacuated and purged with nitrogen. After stirring at room temperature for 30 min, 25 mg of 7-(piperazin-1-yl)-5H-pyrido[4,3-b]indole was added. The reaction progress was monitored by thin-layer chromatography. After the reaction was completed, the mixture was extracted with ethyl acetate, and the organic phases were combined, dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified by silica gel column chromatography with a volume ratio of dichloromethane:methanol = 150:1 to obtain the yellow solid molecular gel degrading agent DT1, with a yield of 18.00 mg and a yield of 40.56%.

[0044] Nuclear magnetic resonance fluorine spectroscopy analysis was performed on the molecular adhesive degrader DT1, such as... Figure 1 As shown, the result is: 19 F NMR (376 MHz, CDCl3) δ = -62.91.

[0045] The molecular adhesive degrader DT1 was analyzed by 1H NMR spectroscopy, such as... Figure 2As shown, the result is: 1 H NMR (300 MHz, CDCl3) δ = 9.20 (s, 1H), 8.57 (d, J = 5.8 Hz, 1H), 8.05 – 7.92 (m, 2H), 7.83(d, J = 2.1 Hz, 1H), 7.78– 7.67(m, 4H), 7.39 (d, J = 15.7 Hz, 1H), 7.09 (dd,J = 8.6, 2.2 Hz, 1H), 6.99 (d, J = 15.4 Hz, 1H), 3.95 – 3.86 (m, 4H), 3.40–3.37(m, 4H).

[0046] Nuclear magnetic resonance carbon spectroscopy analysis of the molecular adhesive degrader DT1, such as Figure 3 As shown, the result is: 13 C NMR (101 MHz, CDCl3) δ = 164.95, 151.68, 145.85, 144.60, 143.01, 142.20, 141.57, 140.29,134.25, 130.89, 129.50, 128.59, 127.95, 126.27, 125.90, 125.86, 125.82,125.79, 122.44, 121.03, 119.25, 116.55, 114.37, 109.63, 103.18, 67.78, 38.92.

[0047] High-resolution mass spectrometry analysis was performed on the molecular adhesive degrader DT1, such as... Figure 4 As shown, the result is: LC–MS (ESI-TOF)calcd for C 25 H 22 F3N4O + [M+H] + The result was 451.1740; found: 451.17417, consistent with the theoretical calculation, with an accuracy within 2.766 ppm. The experiment was conducted in positive ion mode using an electrospray ionization (ESI) source.

[0048] The structure of the molecular adhesive degrader DT1 is shown below, as described above:

[0049]

[0050] Example 2: Preparation of DT2, a molecular adhesive degrader

[0051] Synthesize according to the following route:

[0052]

[0053] 45 mg of 4-trifluoromethylcinnamic acid and 64 mg of HATU were added to a reaction flask, along with 2.00 mL of N,N-dimethylformamide as a solvent. After stirring, 161 mg of N,N-diisopropylethylamine was added, and the mixture was evacuated and purged with nitrogen. After stirring at room temperature for 30 min, 50 mg of 7-[(piperazin-1-yl)methyl]-5H-pyrido[4,3-b]indole was added. The reaction progress was monitored by thin-layer chromatography. After the reaction was completed, the mixture was extracted with ethyl acetate, and the organic phases were combined, dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified by silica gel column chromatography with a volume ratio of dichloromethane:methanol = 150:1 to obtain the yellow solid molecular gel degrading agent DT2, with a yield of 31.00 mg and a yield of 46.36%.

[0054] Nuclear magnetic resonance fluorine spectroscopy analysis was performed on the molecular adhesive degrader DT2, such as... Figure 5 As shown, the result is: 19 F NMR (376 MHz, CDCl3) δ = -62.74.

[0055] The molecular adhesive degrader DT2 was analyzed by 1H NMR spectroscopy, such as... Figure 6 As shown, the result is: 1 H NMR (300 MHz, CDCl3) δ = 9.35 (s, 1H), 8.66 (d, J = 5.8 Hz, 1H), 8.19 (s, 1H), 8.06 (d, J =1.5 Hz, 1H), 7.91 (dd, J = 5.8, 0.9 Hz, 1H), 7.80 – 7.70(m, 4H), 7.49 (dd, J= 8.0, 1.3 Hz, 1H), 7.42 (d, J = 15.7 Hz, 1H), 6.92 (d, J = 15.5 Hz, 1H), 3.76 (s, 4H), 3.67 (s, 2H), 2.58 (s, 4H).

[0056] Nuclear magnetic resonance carbon spectroscopy analysis of the molecular adhesive degrader DT2, such as Figure 7 As shown, the result is: 13C NMR (101 MHz, CDCl3) δ = 165.59, 164.94, 147.06, 144.87, 143.60, 142.95, 141.15, 138.85,138.73, 137.55, 131.11, 128.75, 127.99, 126.43, 126.39, 126.35, 126.32,125.86, 125.65, 123.30, 122.60, 122.28, 120.55, 119.74, 116.13, 110.19,63.13, 55.82, 43.76.

[0057] High-resolution mass spectrometry analysis was performed on the molecular adhesive degrader DT2, such as... Figure 8 As shown, the result is: LC–MS (ESI-TOF)calcd for C 26 H 24 F3N4O + [M+H] + The result was 465.1897; found: 465.18852, consistent with the theoretical calculation, with an accuracy within 2.766 ppm. The experiment was conducted in positive ion mode using an electrospray ionization (ESI) source.

[0058] The structure of the molecular adhesive degrader DT2 is shown below, as described above:

[0059]

[0060] Example 3: Preparation of DT3, a molecular adhesive degrader

[0061] Synthesize according to the following route:

[0062]

[0063] 50 mg of 4-trifluoromethylcinnamic acid and 97 mg of HATU were added to a reaction flask, along with 2.00 mL of N,N-dimethylformamide as a solvent. After stirring, 130 mg of N,N-diisopropylethylamine was added, and the mixture was evacuated and purged with nitrogen. After stirring at room temperature for 30 min, 50 mg of 7-[6-(piperazin-1-yl)pyridin-3-yl]-5H-pyrido[4,3-b]indole was added. The reaction progress was monitored by thin-layer chromatography. After the reaction was completed, the mixture was extracted with ethyl acetate, and the organic phases were combined, dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified by silica gel column chromatography with a volume ratio of dichloromethane:methanol = 150:1 to obtain the yellow solid molecular gel degrading agent DT3, with a yield of 28.00 mg and a yield of 38.56%.

[0064] Nuclear magnetic resonance fluorine spectroscopy analysis was performed on the molecular adhesive degrader DT3, such as... Figure 9 As shown, the result is: 19 F NMR (376 MHz, CDCl3) δ = -62.89.

[0065] The molecular adhesive degrader DT3 was analyzed by 1H NMR spectroscopy, such as... Figure 10 As shown, the result is 1 H NMR (300 MHz, CDCl3) δ = 8.55 (d, J = 2.5 Hz, 1H), 8.16 (d, J = 8.1 Hz, 1H), 8.05 – 7.98(m, 1H), 7.92 (d, J = 5.6 Hz, 1H), 7.84 (dd, J = 8.8, 2.6 Hz, 1H), 7.78 –7.60 (m, 7H), 7.43 (d, J = 15.7 Hz, 1H), 7.00 (d, J = 15.4 Hz, 1H), 6.77 (d,J = 8.8 Hz, 1H), 3.91 – 3.67 (m, 8H).

[0066] Nuclear magnetic resonance carbon spectroscopy analysis of the molecular adhesive degrader DT3, such as Figure 11 As shown, the result is: 13 C NMR (101 MHz, CDCl3) δ = 165.55, 165.18, 158.42, 147.15, 146.71, 145.00, 143.58, 143.09,141.62, 139.39, 138.79, 137.47, 136.69, 128.75, 128.08, 126.62, 126.38,126.00, 125.96, 125.92, 125.88, 123.11, 122.68, 122.39, 122.19, 121.08,119.46, 113.30, 110.05, 107.10, 45.69, 45.29, 41.91.

[0067] High-resolution mass spectrometry analysis was performed on the molecular adhesive degrader DT3, such as... Figure 12 As shown, the result is: LC–MS (ESI-TOF)calcd for C 30 H 25 F3N5O + [M+H] +The result is 528.2006; found: 528.20109, consistent with the theoretical calculation, with an accuracy within 2.766 ppm. The experiment was conducted in positive ion mode using an electrospray ionization (ESI) source.

[0068] The structure of the molecular adhesive degrader DT3 is shown below, as described above:

[0069]

[0070] Example 4: Preparation of DT4, a molecular adhesive degrader

[0071] Synthesize according to the following route:

[0072]

[0073] 35 mg of 4-trifluoromethylcinnamic acid and 93 mg of HATU were added to a reaction flask, along with 2.00 mL of N,N-dimethylformamide as a solvent. After stirring, 125 mg of N,N-diisopropylethylamine was added, and the mixture was evacuated and purged with nitrogen. After stirring at room temperature for 30 min, 50 mg of 7-[6-(piperazin-1-ylmethyl)pyridin-3-yl]-5H-pyrido[4,3-b]indole was added. The reaction progress was monitored by thin-layer chromatography. After the reaction was completed, the mixture was extracted with ethyl acetate, and the organic phases were combined, dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified by silica gel column chromatography at a volume ratio of dichloromethane:methanol = 150:1 to obtain the yellow solid molecular gel degrading agent DT4, with a yield of 31.00 mg and a yield of 41.36%.

[0074] Nuclear magnetic resonance fluorine spectroscopy analysis was performed on the molecular adhesive degrader DT4, such as... Figure 13 As shown, the result is: 19 F NMR (376 MHz, CDCl3) δ = -62.74.

[0075] The molecular adhesive degrader DT4 was analyzed by 1H NMR spectroscopy, such as... Figure 14 As shown, the result is 1H NMR (300 MHz, CDCl3) δ = 9.36 (s, 1H), 8.91 (d, J = 2.3 Hz, 1H), 8.69 (d, J = 5.8 Hz, 1H), 8.46 (d, J = 1.6 Hz, 1H), 8.21 (d, J = 8.0 Hz, 1H), 8.09 – 7.94 (m, 2H), 7.85 (d, J = 5.8 Hz, 1H), 7.82 – 7.74 (m, 4H), 7.70 – 7.69 (m, 1H), 7.53 (d, J =8.1 Hz, 1H), 7.44 (d, J = 15.7 Hz, 1H), 6.95 (d, J = 15.4 Hz, 1H), 3.80 (d, J= 9.5 Hz, 4H), 3.73 (s, 2H), 2.61 (s, 4H).

[0076] Carbon NMR spectroscopy analysis was performed on the molecular adhesive degrader DT4, such as... Figure 15 As shown, the result is: 13 C NMR (101 MHz, CDCl3) δ = 165.43, 165.07, 158.32, 147.01, 146.61, 144.92, 143.51, 142.97,141.50, 139.30, 138.73, 137.35, 136.58, 132.81, 128.65, 127.97, 126.50,126.27, 125.88, 125.85, 125.81, 125.77, 123.02, 122.55, 122.27, 122.11,119.36, 113.18, 109.98, 106.98, 48.21, 45.59, 45.18, 41.80.

[0077] High-resolution mass spectrometry analysis was performed on the molecular adhesive degrader DT4, such as... Figure 16 As shown, the result is: LC–MS (ESI-TOF)calcd for C 31 H 27 F3N5O + [M+H] + The result was 542.2162; found: 542.21689, consistent with the theoretical calculation, with an accuracy within 2.766 ppm. The experiment was conducted in positive ion mode using an electrospray ionization (ESI) source.

[0078] The structure of the molecular adhesive degrader DT4 is shown below, as described above:

[0079]

[0080] Example 5: DT1, DT2, and DT4 reduce multiple p-Tau epitopes

[0081] To evaluate the effects of DT series compounds on different pathology-related phosphorylated Tau sites, SH-SY5Y cells in logarithmic growth phase were divided into groups of 5 × 10⁶ cells per well. 4 Cells were seeded into six-well plates and incubated at 37 ℃ in a 5% CO2 incubator for approximately 24 h. After cell attachment, different concentrations of DT1, DT2, and DT4 were added for treatment, with each treatment lasting 24 h. DT1 and DT2 were prepared at four concentration gradients: 0 μM, 10 μM, 15 μM, and 20 μM; DT4 was prepared at four concentration gradients: 0 μM, 15 μM, 30 μM, and 40 μM. Each concentration was used in triplicate. After treatment, cells were collected for protein extraction.

[0082] During protein extraction, cells were placed on ice and washed twice with pre-cooled PBS. The extraction was performed at a rate of 1×10⁻⁶ cells / day. 6 Add 80–100 μL of RIPA lysis buffer to each cell. The RIPA lysis buffer should be freshly prepared before use, with the protease inhibitor mixture and phosphatase inhibitor mixture added at a volume ratio of 100:1:1 (i.e., 10 μL of 100× protease inhibitor and 10 μL of 100× phosphatase inhibitor per 1 mL of RIPA lysis buffer). After adding the lysis buffer, incubate on ice for 40 min, vortexing every 5 min. Then centrifuge at 4 °C and 12,000 rpm for 20 min, collecting the supernatant as the total protein sample. Protein concentration is determined using the BCA method. Add 1 / 4 volume of 5× loading buffer to the protein sample, mix well, boil at 100 °C for 10 min, and then cool on ice.

[0083] For Western blot analysis, 20–40 μg of total protein was loaded into each well, along with 5 μL of protein marker. Electrophoresis conditions were 150 V for 40 min. For transfer, methanol-activated PVDF membranes were used at a transfer current of 300 mA for 150 min. After transfer, the PVDF membranes were placed in 5% skim milk and blocked at room temperature with a shaker at 60 rpm for 2 h. After blocking, the membranes were washed three times with TBST buffer for 10 min each time. The membranes were cut according to the molecular weights of the target proteins (p-Tau Thr231, p-Tau Ser396, p-Tau Ser199) and the internal control protein (GAPDH), and the corresponding primary antibodies were added. The membranes were incubated overnight at 4 °C with a shaker at 60 rpm. The following day, the membranes were washed three times with TBST for 10 min each time, and the corresponding secondary antibodies were added and incubated at room temperature for 2 h. After a second wash, chemiluminescence exposure was performed.

[0084] After exposure, the gray values ​​of the bands were quantitatively analyzed, and the relative changes in p-Tau protein levels under different compounds and concentrations were calculated using the untreated control group as a benchmark.

[0085] The results are as follows Figure 17 As shown, DT1, DT2, and DT4 all reduced the level of phosphorylated Tau protein in SH-SY5Y cells, and the overall effect was dose-dependent. DT1 at 20 μM degraded p-Tau Thr231 and p-Tau Ser199 by approximately 90%, and p-Tau Ser396 by nearly 80%. DT2 at 20 μM degraded p-Tau Thr231 by approximately 70%, p-Tau Ser396 by approximately 80%, and p-Tau Ser199 by approximately 90%. DT4 showed weak degradation at lower concentrations, but at 40 μM, it degraded p-Tau Thr231 by approximately 80%, p-Tau Ser396 by approximately 70%, and p-Tau Ser199 by approximately 50%. These results indicate that the molecular gel degrading agents described in this invention can act on multiple disease-related phosphorylated Tau epitopes, and are not effective only for a single phosphorylation site.

Claims

1. A molecular gel degrader targeting phosphorylated Tau, or a pharmaceutically acceptable salt, solvate, crystal form, isotope label, or prodrug thereof, characterized in that, The general structural formula of the molecular adhesive degrader is shown in Formula I: Where R is or n is an integer between 0 and 6.

2. The molecular gel degrader according to claim 1, or its pharmaceutically acceptable salt, solvate, crystal form, isotope label, or prodrug, characterized in that, Molecular adhesive degrading agents are selected from any of the following structures: 、 、 、 。 3. A method for preparing a molecular gel degrader according to claim 1 or 2, or a pharmaceutically acceptable salt, solvate, crystal form, isotope label, or prodrug thereof, characterized in that, Synthesize according to the following route: 。 4. The preparation method according to claim 3, characterized in that: Includes the following steps: 4-Trifluoromethylcinnamic acid and a condensing agent were added to an organic solvent, followed by the addition of an organic base. The mixture was stirred and activated under a protective gas atmosphere, and then compound II was added to continue the reaction. The mixture was then extracted, dried, concentrated, and purified by column chromatography.

5. The preparation method according to claim 4, characterized in that, The condensing agent is one or more of HATU, HBTU, EDCI, DCC or T3P, the organic solvent is one or more of N,N-dimethylformamide, dichloromethane, dimethyl sulfoxide, acetonitrile or tetrahydrofuran, and the organic base is one or more of N,N-diisopropylethylamine, triethylamine, pyridine or N-methylmorpholine.

6. The preparation method according to claim 4, characterized in that, The molar ratio of compound II, 4-trifluoromethylcinnamic acid, condensing agent and organic base is 1:(1.0-1.5):(1.2-3.0):(2.0-6.0).

7. The preparation method according to claim 4, characterized in that, The protective gas is nitrogen; the stirring activation time is 20-60 min, the reaction temperature is 15-35℃, and the reaction time is more than 12 h.

8. A pharmaceutical composition, characterized in that, Includes the molecular gel degrading agent of claim 1 or 2, or its pharmaceutically acceptable salt, solvate, crystal form, isotope label, or prodrug.

9. The use of the molecular gel degrader of claim 1 or 2 or a pharmaceutically acceptable salt, solvate, crystal form, isotope label, or prodrug thereof, or the pharmaceutical composition of claim 8, in the preparation of a medicament for the prevention, relief, and / or treatment of neurodegenerative diseases characterized by abnormal phosphorylation of Tau protein.

10. The application according to claim 9, characterized in that, Neurodegenerative diseases include Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, Pick's disease, corticobasal degeneration and / or argyrophilic granulation disease.